Studies_NNS of_IN the_DT actions_NNS of_IN platelet-activating_JJ factor_NN have_VBP centered_VBN mainly_RB around_IN neutrophils_NNS ,_, monocytes_NNS ,_, and_CC platelets_NNS ._.
The_DT long_JJ terminal_JJ repeat_NN LTR_NN of_IN the_DT type_NN 1_CD human_JJ immunodeficiency_NN virus_NN HIV-1_NN and_CC the_DT regulatory_JJ region_NN of_IN the_DT gene_NN encoding_VBG the_DT interleukin_NN 2_CD receptor_NN alpha_NN subunit_NN IL-2R_NN alpha_NN share_NN functional_JJ kappa_NN B_NN enhancer_NN elements_NNS involved_VBN in_IN the_DT regulation_NN of_IN these_DT inducible_JJ transcription_NN units_NNS during_IN T-cell_NN activation_NN ._.
One_CD type_NN ,_, ,_, is_VBZ located_JJ in_IN the_DT upstream_JJ promoter_NN region_NN ,_, and_CC the_DT other_JJ ,_, E-LRB-gre-RRB-_NN ,_, is_VBZ located_JJ in_IN a_DT tandem_JJ repeat_NN with_IN enhancer_NN properties_NNS ._.
Structurally_RB related_JJ divalent_JJ cations_NNS like_IN cobalt_NN ,_, nickel_NN ,_, and_CC mercury_NN also_RB partially_RB increase_VBP monokine_NN secretion_NN but_CC to_TO a_DT much_RB lower_JJR and_CC thus_RB insignificant_JJ extent_NN ._.
Thus_RB the_DT inhibitory_JJ effect_NN of_IN insulin_NN on_IN the_DT GR_NN binding_NN power_NN is_VBZ both_CC dose-_NN and_CC time-dependent_JJ ,_, which_WDT strongly_RB suggests_VBZ that_IN GR_NN is_VBZ tonically_RB controlled_VBN by_IN insulin_NN concentration_NN change_NN under_IN physiological_JJ conditions_NNS ._.
We_PRP showed_VBD that_IN both_CC IL-10_NN and_CC IL-4_NN inhibit_VBP LPS-induced_JJ IL-6_NN mRNA_NN and_CC protein_NN expression_NN by_IN inhibiting_VBG the_DT transcription_NN rate_NN of_IN the_DT IL-6_NN gene_NN ._.
Two_CD subclones_NNS were_VBD found_VBN to_TO have_VB an_DT abnormal_JJ response_NN to_TO the_DT protein_NN kinase_NN C_NN PKC_NN activator_NN PMA_NN ._.
They_PRP bind_VBP to_TO the_DT kappa_NN B_NN motifs_NNS with_IN different_JJ relative_JJ affinities_NNS that_WDT may_MD reflect_VB different_JJ contribution_NN in_IN the_DT expression_NN of_IN various_JJ promoters_NNS ._.
Calcineurin_NN mutants_NNS render_VBP T_NN lymphocytes_NNS resistant_JJ to_TO cyclosporin_NN A_NN ._.
In_IN contrast_NN to_TO peptide_NN vaccination_NN ,_, immunization_NN with_IN adenovirus_NN ,_, expressing_VBG Ad5E1A_NN ,_, induced_VBD Ad5E1A-specific_JJ immunity_NN and_CC prevented_VBD the_DT outgrowth_NN of_IN Ad5E1A-expressing_JJ tumors_NNS ._.
